title: Vedolizumab (Entyvio) for inflammatory bowel disease.
mesh_terms: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015815:Cell Adhesion Molecules; D017277:Drug Approval; D006801:Humans; D007136:Immunoglobulins / Q000378:metabolism; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D009088:Mucoproteins / Q000378:metabolism; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015815:Cell Adhesion Molecules; D007136:Immunoglobulins; C504265:MADCAM1 protein, human; D009088:Mucoproteins; C543529:vedolizumab